Skip to main navigation

About
- Team
- Contact
Research & Development
Pipeline
- RMC-4630
- Mutant RAS
- SOS1
- RMC-5552
Investors
Careers

Press Releases

Press Releases

Year

October 24, 2020

Revolution Medicines Reports Progress and Expansion of Combination Strategy with RMC-4630 as Therapeutic Backbone for RAS-Addicted Cancers

October 12, 2020

Revolution Medicines to Present Interim Data at ENA 2020 from Phase 1b/2 Clinical Trial Combining RMC-4630 with Cobimetinib for RAS-Addicted Solid Tumors

September 16, 2020

Revolution Medicines Reports Preclinical Tumor Regressions Induced by First-in-Class KRAS-G12D(ON) Inhibitors

September 9, 2020

Revolution Medicines to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

September 8, 2020

Revolution Medicines to Participate in 2nd Annual RAS-Targeted Drug Development Conference

August 10, 2020

Revolution Medicines Reports Second Quarter 2020 Financial Results and Provides Update on Corporate Progress

July 13, 2020

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

July 8, 2020

Revolution Medicines Announces Pricing of $156.0 Million Public Offering of Common Stock

July 6, 2020

Revolution Medicines Announces Proposed Public Offering of Common Stock

June 30, 2020

Revolution Medicines Reports New Application of Tri-Complex Modality for “Undruggable” Protein Targets and Announces License to Ginkgo Bioworks to Explore Potential Use Against Novel Coronavirus

Pagination

Current page 1
Page 2
Page 3
Page 4
Page 5
Next page
Last page

Displaying 1 - 10 of 45

Email Alerts

RSS Feeds

Print Page

Contact IR

© 2020 Revolution Medicines, Inc. | 700 Saginaw Drive | Redwood City, CA 94063

Search Investor Relations